January 29, 2010
Bioniche E. coli O157 Vaccine Recognized in Prestigious Scientific Journal

November 25, 2009
Bioniche Strengthens the International Patent Portfolio for its MCC Technology Platform

Check latest
stock price

All prices delayed at least 15 minutes.
Source: TSX Inc.

Bioniche Therapeutics is responsible for scientific discovery, pre-clinical research, clinical studies, regulatory submissions, as well as the development and commercialization of human health products derived from proprietary technologies.

Therapeutic Focus

Discovery research at Bioniche focuses primarily on areas of medicine where there is a strong need for safer, more efficacious therapies: specifically in oncology and immunomodulation.

Pre-clinical research and formulation research is conducted in the company's facilities located within the Bioniche Therapeutics Research Centre at the NRC Biotechnology Research Institute in Montreal, Quebec.

Clinical Studies

Bioniche initiated its Phase III bladder cancer clinical program in November, 2006. The program includes two Phase III trials, one of which is recruiting patients.

The first Phase III trial involves 105 patients in an open-label protocol showing the efficacy of a formulation of MCC – to be known as UrocidinTM when commercialized - as a therapy in non muscle-invasive bladder cancer that is refractory (unresponsive) to Bacillus Calmette-Guérin (BCG). BCG is a live, attenuated strain of Mycobacterium bovis and is often associated with treatment-limiting side effects including active bacterial infections.

The second Phase III trial will enrol approximately 800 patients in North America, Australia and Europe and is a double-blind, randomized study. It will compare MCC to the standard treatment for non muscle-invasive bladder cancer at high risk of recurrence or progression – BCG.

For more information about the Company’s clinical program in bladder cancer, please contact Bioniche Therapeutics at clinicaltrials@bioniche.com.

Beyond its Canadian licensed cattle vaccine against E. coli O157:H7, trademarked Econiche, Bioniche Food Safety has a pipeline of vaccines in development. These include vaccines against Salmonella, Campylobacter and Listeria, all of which are diseases harboured by animals that can cause human illness.